Bindarit was chosen because it causes dose dependent selective inhibition of monocyte chemotactic proteins CCL2, CCL7, CCL8 and has anti-inflammatory efficacy in animal disease models in vivo. The gene discussed is CCL8; the disease is glycogen storage disease VI.